BioSpace News Archive

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma-- First anti-PD-1 antibody from China to receive BTD

Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation (BTD) to Toripalimab for the treatment of nasopharyngeal carcinoma.

September 10, 2020
·
5 min read
Deals

10x Genomics Announces Pricing of Upsized Public Offering - Sep 11, 2020

10x Genomics, Inc. announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions.

September 10, 2020
·
3 min read
Quotient Limited Announces Upsize and Pricing of Underwritten Offering of Ordinary Shares

Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.

September 10, 2020
·
4 min read